Results 21 to 30 of about 1,358,747 (402)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer, 2022
Conditional survival estimates provide critical prognostic information for patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional survival outcomes were assessed in CheckMate 214 (ClinicalTrials.gov identifier NCT02231749 ...
R. Motzer, D. McDermott, B. Escudier, M. Burotto, T. Choueiri, H. Hammers, P. Barthélémy, E. Plimack, C. Porta, S. George, T. Powles, F. Donskov, H. Gurney, C. Kollmannsberger, M. Grimm, C. Barrios, Y. Tomita, D. Castellano, V. Grünwald, B. Rini, M. McHenry, Chung-Wei Lee, Jennifer McCarthy, F. Ejzykowicz, N. Tannir   +24 more
semanticscholar   +1 more source

LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway

Cells, 2022
ccRCC is highly immunogenic, yet its underlying immune-related molecular mechanisms are unknown. Leukotriene B4 Receptor 1 (LTB4R), a novel immune-related gene associated in our previous research with the prognosis of ccRCC patients, has been found in ...
Xiao Zhang, Huahui Wu, Xin Yan, Jiajun Ma, Zhao Chen   +4 more
doaj   +1 more source

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

New England Journal of Medicine, 2015
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma.
R. Motzer, B. Escudier, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, T. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. Gauler, Takeshi Ueda, Y. Tomita, F. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. Simon, Li-an Xu, I. Waxman, Padmanee Sharma   +26 more
semanticscholar   +1 more source

Pancreatic ductal adenocarcinoma concomitant with pancreatic metastases of clear-cell renal cell carcinoma: a case report

Journal of Medical Case Reports, 2021
Background Metastatic spread to the pancreas is a rare event. Renal cell carcinoma represents one possible site of origin of pancreatic metastases. Renal cell carcinoma often metastasizes late and exclusively to the pancreas, suggesting a special role of
Lena Haeberle, Melanie Busch, Julian Kirchner, Georg Fluegen, Gerald Antoch, Wolfram Trudo Knoefel, Irene Esposito   +6 more
doaj   +1 more source

Case Report: Bilateral Renal Cell Carcinoma With Different Histological and Morphological Features, Clear Cell and Cystic Thyroid-Like Follicular Subtype

Frontiers in Oncology, 2021
Thyroid-like follicular renal cell carcinoma is a rare subtype of renal cell carcinoma that has only been recently recognized, as most cases involve a solid tumor in one kidney.
Jinsong Ni, Ni Cui, Yanfang Wang, Jixuan Liu   +3 more
doaj   +1 more source

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

New England Journal of Medicine, 2021
BACKGROUND Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence. METHODS In a double-blind, phase 3 trial, we randomly assigned, in
T. Choueiri, P. Tomczak, S. Park, B. Venugopal, T. Ferguson, Yen‐Hwa Chang, J. Hajek, S. Symeonides, Jae Lyun Lee, N. Sarwar, A. Thiery-Vuillemin, M. Gross-Goupil, M. Mahave, N. Haas, P. Sawrycki, H. Gurney, C. Chevreau, B. Melichar, Evgeniy Kopyltsov, A. Alva, J. Burke, G. Doshi, D. Topart, S. Oudard, H. Hammers, H. Kitamura, J. Bedke, R. Perini, Pingye Zhang, K. Imai, Jaqueline Willemann-Rogerio, D. Quinn, T. Powles   +32 more
semanticscholar   +1 more source

Current trends in renal cell carcinoma

Journal of Medical and Scientific Research, 2014
Kidney cancer is one of the most lethal urological malignancies and surgery was the only treatment of modality a decade ago. Open radical nephrectomy was the procedure of choice for long time for all malignant masses.
Bhardwaj, Gopichand
doaj   +1 more source

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

New England Journal of Medicine, 2019
BACKGROUND The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal‐cell carcinoma.
B. Rini, E. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Soulières, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R. McDermott, J. Bedke, S. Tartas, Yen‐Hwa Chang, S. Tamada, Qiong Shou, R. Perini, Mei Chen, M. Atkins, T. Powles   +26 more
semanticscholar   +1 more source

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

New England Journal of Medicine, 2021
BACKGROUND Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α). METHODS In this phase 2,
E. Jonasch, F. Donskov, O. Iliopoulos, W. Rathmell, V. Narayan, B. Maughan, S. Oudard, T. Else, J. Maranchie, S. Welsh, S. Thamake, E. Park, R. Perini, W. Linehan, R. Srinivasan   +14 more
semanticscholar   +1 more source

Hereditary papillary renal cell carcinoma primarily diagnosed in a cervical lymph node: a case report of a 30-year-old woman with multiple metastases

BMC Urology, 2013
Background Papillary renal cell carcinoma is a rare cancer. Some cases can be attributed to individuals with hereditary renal cell carcinomas usually consisting of the clear cell subtype.
Behnes Carl Ludwig, Schlegel Christina, Shoukier Moneef, Magiera Isabella, Henschke Frank, Schwarz Alexander, Bremmer Felix, Loertzer Hagen   +7 more
doaj   +1 more source